Literature DB >> 25932675

Targeting cancer with kinase inhibitors.

Stefan Gross, Rami Rahal, Nicolas Stransky, Christoph Lengauer, Klaus P Hoeflich.   

Abstract

Kinase inhibitors have played an increasingly prominent role in the treatment of cancer and other diseases. Currently, more than 25 oncology drugs that target kinases have been approved, and numerous additional therapeutics are in various stages of clinical evaluation. In this Review, we provide an in-depth analysis of activation mechanisms for kinases in cancer, highlight recent successes in drug discovery, and demonstrate the clinical impact of selective kinase inhibitors. We also describe the substantial progress that has been made in designing next-generation inhibitors to circumvent on-target resistance mechanisms, as well as ongoing strategies for combining kinase inhibitors in the clinic. Last, there are numerous prospects for the discovery of novel kinase targets, and we explore cancer immunotherapy as a new and promising research area for studying kinase biology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25932675      PMCID: PMC4463189          DOI: 10.1172/JCI76094

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  147 in total

1.  Improved overall survival in melanoma with combined dabrafenib and trametinib.

Authors:  Caroline Robert; Boguslawa Karaszewska; Jacob Schachter; Piotr Rutkowski; Andrzej Mackiewicz; Daniil Stroiakovski; Michael Lichinitser; Reinhard Dummer; Florent Grange; Laurent Mortier; Vanna Chiarion-Sileni; Kamil Drucis; Ivana Krajsova; Axel Hauschild; Paul Lorigan; Pascal Wolter; Georgina V Long; Keith Flaherty; Paul Nathan; Antoni Ribas; Anne-Marie Martin; Peng Sun; Wendy Crist; Jeff Legos; Stephen D Rubin; Shonda M Little; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

Review 2.  Protein kinases--the major drug targets of the twenty-first century?

Authors:  Philip Cohen
Journal:  Nat Rev Drug Discov       Date:  2002-04       Impact factor: 84.694

3.  Immunosuppressive mechanisms of regulatory dendritic cells in cancer.

Authors:  Galina V Shurin; Yang Ma; Michael R Shurin
Journal:  Cancer Microenviron       Date:  2013-06-09

4.  Structure and chemical inhibition of the RET tyrosine kinase domain.

Authors:  Phillip P Knowles; Judith Murray-Rust; Svend Kjaer; Rizaldy P Scott; Sarah Hanrahan; Massimo Santoro; Carlos F Ibáñez; Neil Q McDonald
Journal:  J Biol Chem       Date:  2006-08-23       Impact factor: 5.157

5.  BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships.

Authors:  Jamshid S Khorashad; Todd W Kelley; Philippe Szankasi; Clinton C Mason; Simona Soverini; Lauren T Adrian; Christopher A Eide; Matthew S Zabriskie; Thoralf Lange; Johanna C Estrada; Anthony D Pomicter; Anna M Eiring; Ira L Kraft; David J Anderson; Zhimin Gu; Mary Alikian; Alistair G Reid; Letizia Foroni; David Marin; Brian J Druker; Thomas O'Hare; Michael W Deininger
Journal:  Blood       Date:  2012-12-05       Impact factor: 22.113

6.  Myeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammation.

Authors:  Michael C Schmid; Judith A Varner
Journal:  J Oncol       Date:  2010-05-16       Impact factor: 4.375

Review 7.  The ron receptor tyrosine kinase: a key regulator of inflammation and cancer progression.

Authors:  Xin Wang; Pamela A Hankey
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

8.  Proteome-wide post-translational modification statistics: frequency analysis and curation of the swiss-prot database.

Authors:  George A Khoury; Richard C Baliban; Christodoulos A Floudas
Journal:  Sci Rep       Date:  2011-09-13       Impact factor: 4.379

9.  Inhibition of the kinase Csk in thymocytes reveals a requirement for actin remodeling in the initiation of full TCR signaling.

Authors:  Ying Xim Tan; Boryana N Manz; Tanya S Freedman; Chao Zhang; Kevan M Shokat; Arthur Weiss
Journal:  Nat Immunol       Date:  2013-12-08       Impact factor: 25.606

10.  Protein kinase C-η controls CTLA-4-mediated regulatory T cell function.

Authors:  Kok-Fai Kong; Guo Fu; Yaoyang Zhang; Tadashi Yokosuka; Javier Casas; Ann J Canonigo-Balancio; Stephane Becart; Gisen Kim; John R Yates; Mitchell Kronenberg; Takashi Saito; Nicholas R J Gascoigne; Amnon Altman
Journal:  Nat Immunol       Date:  2014-04-06       Impact factor: 25.606

View more
  156 in total

1.  A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis.

Authors:  Stefanie Galbán; April A Apfelbaum; Carlos Espinoza; Kevin Heist; Henry Haley; Karan Bedi; Mats Ljungman; Craig J Galbán; Gary D Luker; Marcian Van Dort; Brian D Ross
Journal:  Mol Cancer Ther       Date:  2017-08-03       Impact factor: 6.261

Review 2.  Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature.

Authors:  Megan O Jacus; Vinay M Daryani; K Elaine Harstead; Yogesh T Patel; Stacy L Throm; Clinton F Stewart
Journal:  Clin Pharmacokinet       Date:  2016-03       Impact factor: 6.447

3.  Identifying Candidate Druggable Targets in Canine Cancer Cell Lines Using Whole-Exome Sequencing.

Authors:  Sunetra Das; Rupa Idate; Kathryn E Cronise; Daniel L Gustafson; Dawn L Duval
Journal:  Mol Cancer Ther       Date:  2019-06-07       Impact factor: 6.261

4.  Systematic computational identification of promiscuity cliff pathways formed by inhibitors of the human kinome.

Authors:  Filip Miljković; Martin Vogt; Jürgen Bajorath
Journal:  J Comput Aided Mol Des       Date:  2019-03-26       Impact factor: 3.686

Review 5.  Applications of chemogenomic library screening in drug discovery.

Authors:  Lyn H Jones; Mark E Bunnage
Journal:  Nat Rev Drug Discov       Date:  2017-01-20       Impact factor: 84.694

6.  Integration of protein phosphorylation, acetylation, and methylation data sets to outline lung cancer signaling networks.

Authors:  Mark Grimes; Benjamin Hall; Lauren Foltz; Tyler Levy; Klarisa Rikova; Jeremiah Gaiser; William Cook; Ekaterina Smirnova; Travis Wheeler; Neil R Clark; Alexander Lachmann; Bin Zhang; Peter Hornbeck; Avi Ma'ayan; Michael Comb
Journal:  Sci Signal       Date:  2018-05-22       Impact factor: 8.192

7.  Rapid expansion in the WAVE bioreactor of clinical scale cells for tumor immunotherapy.

Authors:  Yiming Meng; Jing Sun; Tingting Hu; Yushu Ma; Tiaozhao Du; Cuicui Kong; Guirong Zhang; Tao Yu; Haozhe Piao
Journal:  Hum Vaccin Immunother       Date:  2018-06-28       Impact factor: 3.452

8.  A potent, selective, and orally bioavailable inhibitor of the protein-tyrosine phosphatase PTP1B improves insulin and leptin signaling in animal models.

Authors:  Navasona Krishnan; Konstantis F Konidaris; Gilles Gasser; Nicholas K Tonks
Journal:  J Biol Chem       Date:  2017-12-07       Impact factor: 5.157

Review 9.  The impact of phosphatases on proliferative and survival signaling in cancer.

Authors:  Goutham Narla; Jaya Sangodkar; Christopher B Ryder
Journal:  Cell Mol Life Sci       Date:  2018-05-03       Impact factor: 9.261

10.  Overcoming Resistance to Targeted Anticancer Therapies through Small-Molecule-Mediated MEK Degradation.

Authors:  Jessie Peh; Matthew W Boudreau; Hannah M Smith; Paul J Hergenrother
Journal:  Cell Chem Biol       Date:  2018-06-14       Impact factor: 8.116

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.